{"filing":{"accession_number":"0001129928-26-000039","cik":"0001129928","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"oncy-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000039/oncy-20260602.htm"},"events":[{"id":7409,"run_id":6509,"accession_number":"0001129928-26-000039","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"On June 1, 2026, Oncolytics Biotech appointed John McAdory as Chief Operating Officer and Stephen Glover as a director. These senior leadership appointments represent material changes to the company's governance and management structure.","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3498,"accession_number":"0001129928-26-000039","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses two executive appointments on June 1, 2026: John McAdory as Chief Operating Officer and Stephen Glover as a director. The principal disclosed action is the appointment of these individuals to new roles. While the filing also mentions equity compensation for Mr. Glover (96,000 stock options), the core event is the appointment itself, not the compensation arrangement. This is material as it involves senior leadership changes at the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:12:08.143719+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3499,"accession_number":"0001129928-26-000039","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses two executive appointments: Stephen Glover to the Board and John McAdory as Chief Operating Officer. While disclosed under Item 8.01 (Other Events), the substance is clearly an executive appointment event. The appointment of a COO and board member are material changes to the registrant's governance and management structure that would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:12:08.143719+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3498,"accession_number":"0001129928-26-000039","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses two executive appointments on June 1, 2026: John McAdory as Chief Operating Officer and Stephen Glover as a director. The principal disclosed action is the appointment of these individuals to new roles. While the filing also mentions equity compensation for Mr. Glover (96,000 stock options), the core event is the appointment itself, not the compensation arrangement. This is material as it involves senior leadership changes at the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:12:08.143719+00:00","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-06-02"},{"id":3499,"accession_number":"0001129928-26-000039","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses two executive appointments: Stephen Glover to the Board and John McAdory as Chief Operating Officer. While disclosed under Item 8.01 (Other Events), the substance is clearly an executive appointment event. The appointment of a COO and board member are material changes to the registrant's governance and management structure that would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:12:08.143719+00:00","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-06-02"}]}